Trial Profile
Phase I trial of mesencephalic astrocyte-derived neurotrophic factor (MANF) as a potential therapy for retinitis pigmentosa.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 19 May 2015
Price :
$35
*
At a glance
- Drugs Mesencephalic astrocyte-derived neurotrophic factor (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- Sponsors Amarantus Bioscience Holdings
- 19 May 2015 New trial record